These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 18207611

  • 1. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
    Baek RC, Kasperzyk JL, Platt FM, Seyfried TN.
    Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
    [Abstract] [Full Text] [Related]

  • 2. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
    Kasperzyk JL, El-Abbadi MM, Hauser EC, D'Azzo A, Platt FM, Seyfried TN.
    J Neurochem; 2004 May; 89(3):645-53. PubMed ID: 15086521
    [Abstract] [Full Text] [Related]

  • 3. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
    Andersson U, Smith D, Jeyakumar M, Butters TD, Borja MC, Dwek RA, Platt FM.
    Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mechanism of abnormal growth in astrocytes derived from a mouse model of GM2 gangliosidosis.
    Kawashima N, Tsuji D, Okuda T, Itoh K, Nakayama K.
    J Neurochem; 2009 Nov; 111(4):1031-41. PubMed ID: 19765188
    [Abstract] [Full Text] [Related]

  • 11. Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice.
    Arthur JR, Wilson MW, Larsen SD, Rockwell HE, Shayman JA, Seyfried TN.
    Neurochem Res; 2013 Apr; 38(4):866-75. PubMed ID: 23417430
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
    Pelled D, Lloyd-Evans E, Riebeling C, Jeyakumar M, Platt FM, Futerman AH.
    J Biol Chem; 2003 Aug 08; 278(32):29496-501. PubMed ID: 12756243
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
    Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA, Platt FM.
    Proc Natl Acad Sci U S A; 1999 May 25; 96(11):6388-93. PubMed ID: 10339597
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease.
    Baek RC, Martin DR, Cox NR, Seyfried TN.
    Lipids; 2009 Mar 25; 44(3):197-205. PubMed ID: 19034545
    [Abstract] [Full Text] [Related]

  • 20. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration.
    Kyrkanides S, Miller JH, Brouxhon SM, Olschowka JA, Federoff HJ.
    Brain Res Mol Brain Res; 2005 Feb 18; 133(2):286-98. PubMed ID: 15710246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.